Editas Medicine Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
87
- Stock Symbol
-
EDIT
- Investments
-
1
- Share Price
-
$1.64
- (As of Friday Closing)
Editas Medicine General Information
Description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Contact Information
Website
www.editasmedicine.comCorporate Office
- 11 Hurley Street
- Cambridge, MA 02141
- United States
Corporate Office
- 11 Hurley Street
- Cambridge, MA 02141
- United States
Editas Medicine Stock Performance
As of 20-Nov-2026, Editas Medicine’s stock price is $1.64. Its current market cap is $253M with 154M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.64 | $1.71 | $1.63 - $3.94 | $253M | 154M | 2.62M | -$0.60 |
Editas Medicine Financials Summary
As of 30-Sep-2026, Editas Medicine has a trailing 12-month revenue of $49.8M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 198,567 | 54,122 | (121,764) | 512,348 |
| Revenue | 49,827 | 40,520 | 32,314 | 78,123 |
| EBITDA | (73,607) | (156,899) | (245,346) | (164,721) |
| Net Income | (72,225) | (160,060) | (237,093) | (153,219) |
| Total Assets | 219,412 | 186,534 | 341,589 | 499,153 |
| Total Debt | 13,941 | 18,102 | 35,032 | 36,536 |
Editas Medicine Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Editas Medicine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Editas Medicine Comparisons
Industry
Financing
Details
Editas Medicine Competitors (52)
One of Editas Medicine’s 52 competitors is Intellia Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Verve Therapeutics | Formerly VC-backed | Boston, MA | ||||
| EdiGene | Venture Capital-Backed | Beijing, China |
Editas Medicine Patents
Editas Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260242779-A1 | Crispr-related methods and compositions targeting low-density lipoprotein receptor (ldlr) | Pending | 15-Jan-2025 | ||
| WO-2026156101-A2 | Crispr-related methods and compositions targeting low-density lipoprotein receptor (ldlr) | Pending | 15-Jan-2025 | ||
| WO-2026156101-A3 | Crispr-related methods and compositions targeting low-density lipoprotein receptor (ldlr) | Pending | 15-Jan-2025 | ||
| WO-2026102260-A1 | Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3) | Pending | 08-Nov-2024 | ||
| WO-2026064475-A1 | Crispr cas-related methods and compositions targeting ptpn2 expression | Pending | 18-Sep-2024 | C12N15/1137 |
Editas Medicine Signals
Editas Medicine Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Editas Medicine Acquisitions (1)
Editas Medicine’s most recent deal was a Merger/Acquisition with i2 Pharmaceuticals for . The deal was made on 22-Jan-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| i2 Pharmaceuticals | 22-Jan-2018 | Merger/Acquisition | Drug Discovery |
Editas Medicine ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
22.6 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Editas Medicine FAQs
-
When was Editas Medicine founded?
Editas Medicine was founded in 2013.
-
Where is Editas Medicine headquartered?
Editas Medicine is headquartered in Cambridge, MA.
-
What is the size of Editas Medicine?
Editas Medicine has 87 total employees.
-
What industry is Editas Medicine in?
Editas Medicine’s primary industry is Drug Discovery.
-
Is Editas Medicine a private or public company?
Editas Medicine is a Public company.
-
What is Editas Medicine’s stock symbol?
The ticker symbol for Editas Medicine is EDIT.
-
What is the current stock price of Editas Medicine?
As of 20-Nov-2026 the stock price of Editas Medicine is $1.64.
-
What is the current market cap of Editas Medicine?
The current market capitalization of Editas Medicine is $253M.
-
What is Editas Medicine’s current revenue?
The trailing twelve month revenue for Editas Medicine is $49.8M.
-
Who are Editas Medicine’s competitors?
Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences, Verve Therapeutics, and EdiGene are some of the 52 competitors of Editas Medicine.
-
What is Editas Medicine’s annual earnings per share (EPS)?
Editas Medicine’s EPS for 12 months was -$0.60.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process